Omid Farokhzad, Seer CEO

Omid Farokhzad’s biotech in­sid­ers SPAC opens the deal win­dow with $200M to play with

Omid Farokhzad’s SPAC is now in play af­ter rais­ing $200 mil­lion — trig­ger­ing a green light for deal talks.

The Seer CEO, ex-Har­vard pro­fes­sor and se­r­i­al start­up ex­ec teamed with for­mer Il­lu­mi­na CTO Mostafa Ron­aghi on the raise, gain­ing the sup­port of his MIT men­tor Bob Langer on this new play.

The group be­hind this SPAC is deeply con­nect­ed in the biotech field, up­ping their chances of tak­ing a uni­corn biotech in­to Nas­daq with a big new raise. The crew in­cludes Mark Afrasi­abi, who had co-head­ed the in­vest­ment com­mit­tee at Sil­ver Rock Fi­nan­cial. There’s al­so CBO Rowan Chap­man out of J&J In­no­va­tion and 3 in­de­pen­dent board mem­bers: David Ep­stein, the for­mer No­var­tis phar­ma chief now at Flag­ship, for­mer Il­lu­mi­na CEO Jay Flat­ley and se­nior man­ag­ing part­ner of the Soft­Bank Vi­sion Fund, Deep Nishar.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.